This company listing is no longer active
Jilin Zixin Pharmaceutical IndustrialLtd Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Jilin Zixin Pharmaceutical IndustrialLtd's earnings have been declining at an average annual rate of -66.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 50.2% per year.
Wichtige Informationen
-66.3%
Wachstumsrate der Gewinne
-66.6%
EPS-Wachstumsrate
Pharmaceuticals Wachstum der Industrie | 10.9% |
Wachstumsrate der Einnahmen | -50.2% |
Eigenkapitalrendite | -87.3% |
Netto-Marge | -793.4% |
Nächste Ertragsaktualisierung | 23 Aug 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Jilin Zixin Pharmaceutical IndustrialLtd Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
31 Mar 23 | 150 | -1,189 | 655 | 4 |
31 Dec 22 | 144 | -1,189 | 650 | 7 |
30 Sep 22 | 145 | -1,219 | 630 | 8 |
30 Jun 22 | 153 | -1,178 | 595 | 13 |
31 Mar 22 | 192 | -1,105 | 592 | 12 |
01 Jan 22 | 247 | -998 | 556 | 10 |
30 Sep 21 | 248 | -770 | 267 | 17 |
30 Jun 21 | 294 | -698 | 286 | 12 |
31 Mar 21 | 289 | -696 | 264 | 17 |
31 Dec 20 | 286 | -706 | 283 | 16 |
30 Sep 20 | 343 | -280 | 310 | 15 |
30 Jun 20 | 463 | -201 | 273 | 16 |
31 Mar 20 | 756 | -20 | 336 | 37 |
31 Dec 19 | 859 | 70 | 318 | 40 |
30 Sep 19 | 760 | -82 | 296 | 66 |
30 Jun 19 | 997 | -45 | 372 | 76 |
31 Mar 19 | 1,141 | 19 | 356 | 46 |
31 Dec 18 | 1,325 | 174 | 356 | 46 |
30 Sep 18 | 1,854 | 542 | 433 | 46 |
30 Jun 18 | 1,715 | 538 | 415 | 41 |
31 Mar 18 | 1,493 | 472 | 388 | 45 |
31 Dec 17 | 1,327 | 372 | 381 | 41 |
30 Sep 17 | 1,006 | 247 | 302 | 7 |
30 Jun 17 | 925 | 253 | 279 | 0 |
31 Mar 17 | 859 | 188 | 287 | 0 |
31 Dec 16 | 820 | 163 | 283 | 0 |
30 Sep 16 | 874 | 142 | 301 | 0 |
30 Jun 16 | 755 | 57 | 295 | 0 |
31 Mar 16 | 666 | 45 | 274 | 0 |
31 Dec 15 | 633 | 40 | 271 | 0 |
30 Sep 15 | 689 | 68 | 246 | 0 |
30 Jun 15 | 690 | 73 | 250 | 0 |
31 Mar 15 | 663 | 47 | 264 | 0 |
31 Dec 14 | 776 | 47 | 271 | 0 |
30 Sep 14 | 568 | -30 | 272 | 0 |
30 Jun 14 | 579 | 7 | 244 | 0 |
31 Mar 14 | 626 | 37 | 222 | 0 |
31 Dec 13 | 475 | 50 | 196 | 0 |
30 Sep 13 | 411 | 52 | 164 | 0 |
30 Jun 13 | 372 | 51 | 153 | 0 |
31 Mar 13 | 430 | 97 | 135 | 0 |
31 Dec 12 | 419 | 86 | 132 | 0 |
30 Sep 12 | 716 | 126 | 222 | 0 |
Qualität der Erträge: 002118 is currently unprofitable.
Wachsende Gewinnspanne: 002118 is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 002118 is unprofitable, and losses have increased over the past 5 years at a rate of 66.3% per year.
Beschleunigtes Wachstum: Unable to compare 002118's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: 002118 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.6%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 002118 has a negative Return on Equity (-87.33%), as it is currently unprofitable.